Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 348 participants.

Also called NCT07509645

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 348 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07509645
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07509645. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-22 (actual); primary completion 2027-04-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
Acronym
IRIS-3
Intervention (Drug)
Tocilizumab
Intervention (Drug)
Placebo
Lead sponsor
Capital Medical University (class: other)

Record details

Record id
cardio:ct-nct07509645
Content hash
85729e3e88c0d88c3817c7aaa659b48250ed10ea9d8c08fdd5202431b47eda01